EPC1
Overview
EPC1 (Enhancer of Polycomb Homolog 1) is a component of the NuA4/Tip60 histone acetyltransferase complex involved in histone acetylation and chromatin modification. It was identified as a novel significantly mutated gene in pancreatic ductal adenocarcinoma (PDAC) through whole-exome sequencing, implicating chromatin remodeling dysregulation as a driver mechanism in pancreatic cancer.
Alterations observed in the corpus
- Novel significantly mutated gene in pancreatic ductal adenocarcinoma (ICGC cohort, 142 tumors); somatic mutations implicate histone acetylation and chromatin modification as a driver pathway PMID:23103869
Cancer types (linked)
- PAAD (pancreatic adenocarcinoma): Identified as a novel significantly mutated gene by ICGC WES of 142 PDAC tumors; mutations affect the histone acetyltransferase complex PMID:23103869
Co-occurrence and mutual exclusivity
- Identified alongside other chromatin remodeling genes (ARID1A, ARID2) as part of a broader pattern of SWI/SNF and NuA4 complex alterations in PDAC PMID:23103869
Therapeutic relevance
- No targeted therapies currently linked to EPC1 in this corpus. Role in histone acetylation suggests potential sensitivity to HDAC or HAT pathway inhibitors.
Open questions
- EPC1 was classified as a novel finding requiring further functional validation; its frequency and co-mutation patterns in larger PDAC cohorts remain to be established PMID:23103869
Sources
This page was processed by entity-page-writer on 2026-05-06.